Sanofi/Re­gen­eron heart drug as­so­ci­ated with 29% lower risk of death

Arab News - - CORPORATE PR -

Sanofi and Re­gen­eron Phar­ma­ceu­ti­cals Inc. have an­nounced that the Odyssey Out­comes trial has met its pri­mary end­point, show­ing that Pralu­ent (Alirocumab) sig­nif­i­cantly re­duced the risk of ma­jor ad­verse car­dio­vas­cu­lar events (MACE) in pa­tients who had suf­fered a re­cent acute coro­nary syn­drome (ACS) event such as a heart at­tack.

A more pro­nounced ef­fect was ob­served in pa­tients with base­line LDL-C lev­els at or above 100 mg/dL de­spite max­i­mally tol­er­ated statins, who are at a high risk of suf­fer­ing a fu­ture event. In this group, Pralu­ent re­duced the risk of ma­jor ad­verse heart events by 24 per­cent and was as­so­ci­ated with a 29 per­cent lower risk of death.

Re­sults from the trial were pre­sented dur­ing a late-breaker ses­sion at the Amer­i­can Col­lege of Car­di­ol­ogy’s 67th An­nual Sci­en­tific Ses­sion (ACC.18) in Or­lando, Florida.

“This trial was consistent with ear­lier statin tri­als, show­ing the great­est ben­e­fit in pa­tients with higher choles­terol lev­els at base­line,” said Ge­orge D. Yan­copou­los, president and chief sci­en­tific of­fi­cer, Re­gen­eron. “Many pa­tients who have sur­vived a re­cent heart at­tack or other coro­nary event are un­able to reach an LDL choles­terol goal of less than 100 mg/dL, and have an ur­gent need for new ther­a­peu­tic op­tions be­cause of their in­creased risk of an­other event. In this trial, such pa­tients who re­ceived Pralu­ent on top of max­i­mally-tol­er­ated statins had im­por­tant re­duc­tions in their risk.”

“Not all pa­tients with heart dis­ease are the same. Through this trial, we have been able to iden­tify high-risk pa­tients treated with op­ti­mal statins who still have an ur­gent need for ad­di­tional treat­ment op­tions,” said Elias Zer­houni, president, global R&D, Sanofi. “With nearly 90 per­cent of the pa­tients in this trial on high-in­ten­sity statins, the data demon­strates that a pre­ci­sion-medicine ap­proach in the field of car­dio­vas­cu­lar dis­ease may fur­ther ad­vance how we bet­ter treat high-risk pa­tients.”

Newspapers in English

Newspapers from Saudi Arabia

© PressReader. All rights reserved.